MEET UGANDAN SCIENTIST ALEX KINTU BEHIND HIV VACCINE WITH 100% PROTECTION FOR WOMEN
Harvard-trained researcher leads breakthrough injectable HIV prevention trial showing perfect efficacy for adolescent girls and young women.
Alex Kintu, a Ugandan scientist working at Gilead Sciences, is spearheading pioneering research on lenacapavir, a twice-yearly injectable designed to prevent HIV infection. Results from the PURPOSE 1 trial demonstrated an unprecedented 100% efficacy in protecting women especially adolescent girls and young women in high-risk regions like South Africa and Uganda.
Kintu’s dedication to this work is personal. Growing up during Uganda’s HIV epidemic, he witnessed firsthand the devastating impact of the virus on families, motivating his drive to develop innovative solutions for underserved populations.
Holding a PhD from Harvard and recognized with multiple Gilead research awards, Kintu symbolizes Uganda’s growing role in global biomedical science. Should lenacapavir receive approval, it promises to revolutionize HIV prevention worldwide.
View this post on Instagram
Source:NKONKONSA.com
